Continuation of The Collaborative Islet Transplantation Registry (CITR)

PROJECT SUMMARY This application, in response to RFA-DK-21-013, describes a comprehensive Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) for 2022-2027. Continuing from 2017-2021 as the CITR-DSCC, Emmes continues to collaborate with the NIDDK Program Office, the Oversight Committee, and the CITR investigators to support the established CITR Registry. The registry includes allogeneic and autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic episodes in persons with Type 1 diabetes or lacking pancreatic islets for any reason including therapeutic pancreatectomy or any loss of islet cell function. For more details, please see the Specific Aims section.